武漢佰樂博代理:Research Grade Telisotuzumab
貨號:DHC34203
產品鏈接:http://www.atagenix.com/product_detail-75316.html
產品購買聯(lián)系方式:027-65279366
產品介紹:Telisotuzumab (ABT-700)是一種人源化重組二價抗體,針對肝細胞生長因子受體(MET)的治療性抗體,可以高親和力結合c-Met并抑制c-Met信號傳導。Telisotuzumab具有抗腫瘤活性。
通用名:Telisotuzumab
純度:>95% by SDS-PAGE.
濃度:1mg/ml
Formulationicon:0.01M PBS, pH 7.4.
內毒素:Please contact with the lab for this information.
別名:ABBV-399, ABT-700-vcMMAE, ABT-700, hz224G11
靶點;物種:Human MET/c-Met/HGFR
種類:Humanized
受體鑒定:IgG1-kappa
CAS: 1781223-80-0
參考文獻:
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). PMID: 33221175
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. PMID: 36288547
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. PMID: 33675179
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. PMID: 35005654
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. PMID: 30285518